Virus and Other Infection-associated Cancers

Friday, June 8, 2018
1:00 PM
SHM I-304

"Prognosis of HPV associated head and neck cancer varies by site: oncogenic implications?"

Benjamin Judson, MD, MPA
Associate Professor, Section of Otolaryngology
Chief Ambulatory Officer, Smilow Cancer Hospital

The VOIC Research Program Seminar Series is hosted by Wendell Yarbrough and Walther Mothes.

Lunch will be provided.
Biostatistics Shared Resource (BSR) Drop-In Office Hours – WWW213

**Biostatistics**
Dr. Wei Wei  
Thursdays - 9am-1pm  
Fridays - 9am-5pm

**Bioinformatics**
Drs. Yong Kong and Ying Zhu  
Fridays - 1pm-5pm
AIDS Center at Yale Announces $7.8 Million Award to Continue Research on Pandemic

May 1, 2018

CIRA Network
Members of CIRA and their partners gather for the New England HIV Implementation Science Network Retreat on March 2 in Mystic, Conn.


The Center for Interdisciplinary Research on AIDS (CIRA) at Yale University has received a new $7.8 million grant from the National Institute of Mental Health to continue its work for the next five years.
Member Notables

Inside YCC
@InsideYCC

Congratulations to VOIC @YaleCancer member Akiko Iwasaki @VirusesImmunity for winning this year's Charles W. Bohmfalk Prize for teaching in the basic sciences!

Akiko Iwasaki @VirusesImmunity
Women killing it this year in @YaleMed awards - selected by students! #YSM2018 #womeninscience #womeninmedicine #keepkillingit

9:58 AM - 23 May 2018

1 Retweet  17 Likes
Recent High Impact and Intra/Inter-Programmatic Member Publications

* Intra-programmatic collaboration
** Inter-programmatic collaboration
*/** Both Intra- and Inter-programmatic collaboration
HIJ Published in a high-impact journal

* Topical application of aminoglycoside antibiotics enhances host resistance to viral infections in a microbiota-independent manner.
Gopinath S, Kim MV, Rakib T, Wong PW, van Zandt M, Barry NA, Kaisho T, Goodman AL, Iwasaki A
Nat Microbiol 3: 611-621 (05/2018)
PM ID: 29632368 PMC5918160 NIHMS946869

** Importance of homo-dimerization of Fanconi-associated nuclease 1 in DNA flap cleavage.
Rao T, Longerich S, Zhao W, Aihara H, Sung P, Xiong Y
DNA Repair (Amst) 64: 53-58 (04/2018)
PM ID: 29518739

** Pediatric Salivary Cancer: Epidemiology, Treatment Trends, and Association of Treatment Modality with Survival.
Morse E, Fujiwara RJT, Husain Z, Judson B, Mehra S
PM ID: 29688836
**SAMHD1 suppresses innate immune responses to viral infections and inflammatory stimuli by inhibiting the NF-κB and interferon pathways.**
Proc Natl Acad Sci U S A 115: E3798-E3807 (04/2018)
PM ID: 29610295 PMC5910870

Oral Oncol 79: 64-70 (04/2018)
PM ID: 29598952
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment, and Care in Low and Middle-Income Countries (R21 Clinical Trial Optional)
(PAR-18-732) AIDS Application Due Date: August 1, 2018
The purpose of this FOA is to stimulate research on interventions to reduce HIV/AIDS-associated stigma and its impact on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH).

HIV/AIDS and the Tumor Niche (R01)
(RFA-CA-17-030) Application Due Date: August 7, 2018
The purpose of this Funding Opportunity Announcement (FOA) is to advance our understanding of the role of the tumor niche or microenvironment in the risks, development, progression, diagnosis, and treatment of cancer observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS).
HIV Funding Opportunities

Comprehensive List check here: http://yalecancercancercenter.org/research/foa.aspx

Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional) (RFA-CA-18-013)

Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R21 Clinical Trial Not Allowed) (RFA-CA-18-014) **Application Due Date: August 16, 2018**
The purpose of these funding opportunity announcements (FOAs) is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and risk factors for infection to inform efforts to prevent KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of developing HIV.

Tobacco Use and HIV in Low and Middle Income Countries (R01) (PAR-17-087) **Application Due Date(s): Any due dates on or after Jan 25, 2018 must use reissued FOA. November 1, 2018; April 4, 2019, November 1, 2019**
The purpose of this funding opportunity announcement (FOA) is to encourage research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.
HIV Funding Opportunities

Comprehensive List check here:
http://yalecancercenter.org/research/foa.aspx

Standard Dates for HIV/AIDS –Related Applications Apply for all of the following FOAs. See the description below, and this link for more information.

<table>
<thead>
<tr>
<th>Activity Codes</th>
<th>Program Description</th>
<th>Cycle I Due Date</th>
<th>Cycle II Due Date</th>
<th>Cycle III Due Date</th>
</tr>
</thead>
</table>
| All Activity Codes Cited Above *new, renewal, resubmission, revision* | **AIDS and AIDS-Related Applications**  
*Effective. Sept 5, 2015 - N/A for SBIR/STTR Applications using Standard Due Dates*  
NOTE: See Key Dates section of funding opportunity announcement to determine if AIDS dates apply. | May 7 | September 7 | January 7 |
HIV Funding Opportunities

Comprehensive List check here: http://yalecancercenter.org/research/foa.aspx

"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R01)
(PA-16-426)

"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R21)
( PA-16-425) Application Due Date(s) **Standard AIDS dates** apply

The purpose of these funding opportunity announcements (FOAs) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals.

HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure through Clinical Research (R01)
(PA-17-279)

HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure through Clinical Research (R21)
(PA-17-278) Application Due Date(s) **Standard AIDS dates** apply

The purpose of these Funding Opportunity Announcements (FOAs) are to fill scientific gaps needed to (a) inform HBV functional cure strategies by furthering our understanding of unique challenges impacting HBV and HIV co-infected hosts and (b) advance the discovery and development of novel HBV interventions that are safe and achieve a functional cure in HIV and HBV co-infected individuals.
HIV Funding Opportunities
Comprehensive List check here:
http://yalecancercenter.org/research/foa.aspx

**In Vitro and Animal Model Studies on HBV/HIV Co-Infection (R01)**
(PA-17-280)

**In Vitro and Animal Model Studies on HBV/HIV Co-Infection (R21)**
(PA-17-281) **Application Due Date(s) Standard AIDS dates**
The purpose of these Funding Opportunity Announcements (FOAs) are to: (a) stimulate and accelerate development of novel in vitro and small animal models of HBV/HIV co-infection to accelerate drug discovery/drug development in HBV/HIV co-infection; and (b) stimulate and accelerate a better understanding of the immunopathogenic interactions between HBV and HIV.

**Multidisciplinary Studies of HIV/AIDS and Aging (R01)**
(PAR-17-321)

**Multidisciplinary Studies of HIV/AIDS and Aging (R21)**
(PAR-17-320) **Application Due Date(s) Any due dates on or after January 25, 2018 must use reissued FOA. Standard dates apply**
These FOAs encourage exploratory/developmental research applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-15-137.
HIV Funding Opportunities

Comprehensive List check here:
http://yalecancercenter.org/research/foa.aspx

Harnessing Big Data to Halt HIV (R01)
(PAR-18-764) Application Due Date(s) Standard AIDS dates apply

The purpose of this Funding Opportunity Announcement (FOA) is to promote research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). This FOA will support projects to assemble diverse big data sources, conduct robust and reproducible analyses, and create meaningful visualizations of big data, as well as, engage ethical experts where appropriate to ensure the development of this scientific area is guided by ethical principles.

To view these FOAs again, go to the archive at yalecancercenter.org/VOICupdate
Upcoming Events

https://medicine.yale.edu/cancer/patient/calendar/

ST Retreat on Translation - Tuesday, October 16th
*Featuring Keynote Speaker David Solit - MSKCC*

West Campus Conference Center | Full Agenda TBD
Did we miss your good news?

Email:
christina.dreyfus@yale.edu

Want to follow-up on something?

These updates will be archived at:
yalecancercenter.org/VOICupdate